@FiercePharma: GSK's Andrew Witty: emerging-markets guru. Report | Follow @FiercePharma
> China's Ministry of Health has published the country's first-ever guidance for doctors on the use of medicines, providing advice on the correct use of a range of widely-prescribed drugs. Report
> GlaxoSmithKline kicked off a 90-day consultation period over its plans to slash a significant number of jobs at its research site in Harlow, England, following a shift in research focus. Report
> Signaling he'd meet critics part way on healthcare, President Obama says he's willing to sign a bill even if it doesn't deliver everything he pursued through a year of grinding effort. Report
> Boehringer Ingelheim announced a tender offer for the 40 percent stake in Japanese OTC drugmaker SSP that it doesn't already own. Report
> Reckitt Benckiser says it is confident for growth in 2010 after reporting fourth-quarter profit that beat analysts' estimates. Report
> Republicans will carry to President Obama's healthcare summit a set of ideas intended to make health insurance more widely available and affordable by emphasizing tax incentives and state innovations. Report
Biotech News
@FierceBiotech: BIO chief Jim Greenwood talks to @JohnCFierce about reform, maps salvage plan for the 12-year umbrella. Article | Follow @FierceBiotech
@JohnCFierce: Dendreon CEO M Gold sounds supremely confident about the Provenge rollout. Follow @JohnCFierce
> Biotech CEOs go to BIO's annual CEO & Investor confab at the Waldorf-Astoria to burnish the reputations of their companies in the heart of the world's financial center. Report
> MDS Pharma Services says that Ricerca Biosciences is buying its discovery and preclinical services business for $45 million. Report
> Adeona Pharmaceuticals has appointed James Kuo as chairman, CEO and president. Report
> Alexza Pharmaceuticals is scooping up a $40 million upfront payment and stands to earn $90 million in milestones after shaking hands with Biovail on a development pact for its inhaled agitation therapy. Story
> Researchers for Genzyme (GENZ) and Isis Pharmaceuticals (ISIS) trumpeted the success of their cholesterol drug mipomersen in a late-stage trial, but investors heard a sour note when the side affects were discussed. Story
> The U.K.'s ReNeuron has been given a regulatory green light to launch the world's first human trial of a stem cell therapy for strokes. Article
> Sanofi-Aventis has been steadily ratcheting down the amount of money it's spending on R&D. Report
And Finally ... The WHO has stopped sending free drugs to private hospitals and NGOs in Haiti after receiving reports that some institutions in the earthquake-stricken country had begun to charge patients. Report